Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in High Risk MDS
NCT00867061Phase 2Withdrawn
- Sponsor
- Traws Pharma, Inc.
- Start
- Mar 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Traws Pharma, Inc. Primary endpoints: Maximum Tolerated Dose at 1 month and Response according to International Working Group criteria. Planned start Mar 2009; status: withdrawn.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00867061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867061.